DDInter407 DDInter1747
Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Clofedanol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Clofedanol {u} (Compound) resembles {v} (Compound) Dextropropoxyphene
Clofedanol {u} (Compound) resembles {v} (Compound) Toremifene
Clofedanol {u} (Compound) binds {v} (Gene) HRH1
Clofedanol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Clofedanol {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Clofedanol (Compound) resembles Dextropropoxyphene (Compound)
Clofedanol (Compound) resembles Toremifene (Compound)
Clofedanol (Compound) binds HRH1 (Gene)
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Clofedanol (Compound) resembles Carbinoxamine (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine